search
Back to results

Medically Reproducing Bariatric Surgery (MRB)

Primary Purpose

Type 2 Diabetes Mellitus

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
OPTIFAST
Sponsored by
Moahad S Dar
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring Roux-en-y gastric bypass, GLP-1, Liraglutide, OPTIFAST

Eligibility Criteria

25 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • male or female
  • age 25-70 years
  • BMI > 30
  • diagnosis of type 2 diabetes
  • weight stable for 3 months
  • hemoglobin A1C >7% and <10%
  • on Liraglutide
  • on Metformin
  • on Lantus
  • interested in losing weight
  • agreeable to regular visits per study protocol
  • access to telephone and reliable transportation
  • has a VAMC provider

Exclusion Criteria:

  • age >70
  • A1C <7% or >10%
  • current use of prandial insulin
  • current use of sulfonylurea or any other oral agent except for Metformin
  • current sue of any other basal insulin except for Lantus
  • pregnant
  • breast feeding
  • prior history of pancreatitis
  • prior history of gastroparesis
  • history of thyroid cancer/multiple endocrine neoplasia/thyroid nodules/medullary thyroid cancer
  • history of gallstones
  • history of hyperoxaluria or calcium oxalate nephrolithiasis
  • AST/ALT > 2 times the upper limit of normal
  • current or past history of liver disease
  • history of Roux-en-Y gastric bypass or gastric sleeve or any other bariatric procedure
  • type 1 diabetes
  • any gastrointestinal disease causing malabsorption
  • unwilling or unable to complete scheduled testing
  • thiazolidinedione use within past 6 months
  • any serious and/or unstable medical, psychiatric, or other condition(s) that prevents the patient from providing informed consent or complying with the study
  • organ transplantation or those on immunosuppressants
  • chronic anticoagulation
  • recent myocardial infarction, unstable angina, stroke, coronary artery bypass or transient ischemia attacks in the past 6 months
  • chronic prednisone use
  • peptic ulcer disease in past 6 months
  • acute gastrointestinal disorders
  • hepatitis
  • cirrhosis
  • GFR < 50
  • deep vein thrombosis in the past 6 months
  • bone fractures in the past 6 months
  • lithium use
  • active malignancy
  • substance abuse
  • unstable psychiatric condition
  • history of suicidal ideation
  • enrolled in another research study related to diet and/or physical activity

Sites / Locations

  • Department of Veteran Affairs, Greenville Health Care Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

OPTIFAST

Arm Description

Subjects meeting inclusion criteria will be receive OPTIFAST meal replacement (MR) in the following manner: WK1-WK12 (5 MR/DAY) WK13-14 (4 MR/DAY) WK 15 (3 MR/DAY) WK 16 (2 MR/DAY) WK 17-18 (1 MR/DAY) WK 19-24 (No MR)

Outcomes

Primary Outcome Measures

Change in Glycemic control
Hemoglobin A1C (HbA1C) will be used to assess glycemic control during the study

Secondary Outcome Measures

Change in Weight
Weight in kilograms will be used to assess weight change during the study
Change in Medication intensity
Medication effect score (MES) will be used to assess medication intensity during the study
Change in Health Related Quality of Life (HRQOL)
Problem Areas in Diabetes Scale (PAID) is a well-validated measure used in clinical trials regarding diabetes and is a sensitive and specific measure of HRQOL.
Change in Health Related Quality of Life
EQ-5D-5L is a highly sensitive 5-item health status measure with good performance in Veteran outpatients. It assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
Change in Physical activity
International Physical Activity Questionnaire (IPAQ) is a well validated tool to assess daily physical activity

Full Information

First Posted
July 5, 2017
Last Updated
January 29, 2020
Sponsor
Moahad S Dar
Collaborators
Société des Produits Nestlé (SPN), Durham VA Medical Center, East Carolina University
search

1. Study Identification

Unique Protocol Identification Number
NCT03225209
Brief Title
Medically Reproducing Bariatric Surgery
Acronym
MRB
Official Title
Medically Reproducing Bariatric Surgery
Study Type
Interventional

2. Study Status

Record Verification Date
January 2020
Overall Recruitment Status
Completed
Study Start Date
January 31, 2018 (Actual)
Primary Completion Date
October 23, 2018 (Actual)
Study Completion Date
October 23, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Moahad S Dar
Collaborators
Société des Produits Nestlé (SPN), Durham VA Medical Center, East Carolina University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Type 2 diabetes (DM2) is a chronic disease affecting 29 million Americans and a leading cause of blindness, kidney failure, and limb loss (Engelgau et al 2004). Roux-en-Y gastric bypass (RYGB) is the only intervention that leads to durable DM2 remission ~ 80% of the time (Mingrone et al 2012). Yet, it's broad application is limited by cost, invasiveness, and clinical inertia. Medically reproducing RYGB would extend the benefit of disease remission to the vast majority of DM2 patients using a cheaper, less invasive and more palatable treatment approach. Although all of the mechanisms mediating DM2 remission are not known, it is widely accepted that RYGB induces caloric restriction and enhances meal-stimulated release of a gut-peptide called glucagon-like-peptide-1 (GLP-1) both of which improve glycemic control in type 2 diabetes (Dar et al 2012; Jackness 2013). Caloric restriction can be achieved using OPTIFAST which is a commercially available medical weight loss program that has demonstrated the ability to decrease weight and improve glycemic control (Kirschner et al; 1998). Enhanced meal-stimulated GLP-1 release can be achieved using Liraglutide an FDA-approved once daily GLP-1 analogue that improves glycemic control and induces weight loss. The investigators hypothesize that adding OPTIFAST (caloric restriction) in suboptimally controlled DM2 patients on Liraglutide (enhanced meal stimulated GLP-1 release), Metformin and Lantus insulin will medically reproduce RYGB and lead to DM2 remission, weight loss, decreased medication intensity and improved health related quality of life.
Detailed Description
This is a 24 week "proof of concept" study that will examine if adding "caloric restriction" (OPTIFAST) to "enhanced GLP-1 release" (Liraglutide) will lead to discontinuation of Lantus and Metformin. The primary outcome measure is change in glycemic control measured as hemoglobin A1C. Secondary outcome measures are change in weight, medication intensity and health related quality of life.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
Keywords
Roux-en-y gastric bypass, GLP-1, Liraglutide, OPTIFAST

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Model Description
"Proof of concept" study
Masking
None (Open Label)
Allocation
N/A
Enrollment
5 (Actual)

8. Arms, Groups, and Interventions

Arm Title
OPTIFAST
Arm Type
Experimental
Arm Description
Subjects meeting inclusion criteria will be receive OPTIFAST meal replacement (MR) in the following manner: WK1-WK12 (5 MR/DAY) WK13-14 (4 MR/DAY) WK 15 (3 MR/DAY) WK 16 (2 MR/DAY) WK 17-18 (1 MR/DAY) WK 19-24 (No MR)
Intervention Type
Other
Intervention Name(s)
OPTIFAST
Intervention Description
OPTIFAST meal replacement includes shakes, bars and soups. These meal replacements will completely replace the subject's diet for the first 12 weeks of the study (baseline-week 12) followed by a gradual transition back to prepared meals over 6 weeks (week 13-18). Attempt will be made to reduce or eliminate Lantus and Metformin as long as glycemic control is maintained.
Primary Outcome Measure Information:
Title
Change in Glycemic control
Description
Hemoglobin A1C (HbA1C) will be used to assess glycemic control during the study
Time Frame
Change in HbA1c from baseline at week 12 and week 24 will be measured
Secondary Outcome Measure Information:
Title
Change in Weight
Description
Weight in kilograms will be used to assess weight change during the study
Time Frame
Change in weight in kilograms from baseline at week 12 and week 24 will be measured
Title
Change in Medication intensity
Description
Medication effect score (MES) will be used to assess medication intensity during the study
Time Frame
Change in MES from baseline at week 12 and week 24 will be measured
Title
Change in Health Related Quality of Life (HRQOL)
Description
Problem Areas in Diabetes Scale (PAID) is a well-validated measure used in clinical trials regarding diabetes and is a sensitive and specific measure of HRQOL.
Time Frame
Change in PAID from baseline at week 12, and week 24 will be measured
Title
Change in Health Related Quality of Life
Description
EQ-5D-5L is a highly sensitive 5-item health status measure with good performance in Veteran outpatients. It assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
Time Frame
Change in EQ-5D-5L from baseline at week 12 and week 24 will be measured
Title
Change in Physical activity
Description
International Physical Activity Questionnaire (IPAQ) is a well validated tool to assess daily physical activity
Time Frame
Change in IPAQ from baseline at week 12 and week 24 will be measured

10. Eligibility

Sex
All
Minimum Age & Unit of Time
25 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: male or female age 25-70 years BMI > 30 diagnosis of type 2 diabetes weight stable for 3 months hemoglobin A1C >7% and <10% on Liraglutide on Metformin on Lantus interested in losing weight agreeable to regular visits per study protocol access to telephone and reliable transportation has a VAMC provider Exclusion Criteria: age >70 A1C <7% or >10% current use of prandial insulin current use of sulfonylurea or any other oral agent except for Metformin current sue of any other basal insulin except for Lantus pregnant breast feeding prior history of pancreatitis prior history of gastroparesis history of thyroid cancer/multiple endocrine neoplasia/thyroid nodules/medullary thyroid cancer history of gallstones history of hyperoxaluria or calcium oxalate nephrolithiasis AST/ALT > 2 times the upper limit of normal current or past history of liver disease history of Roux-en-Y gastric bypass or gastric sleeve or any other bariatric procedure type 1 diabetes any gastrointestinal disease causing malabsorption unwilling or unable to complete scheduled testing thiazolidinedione use within past 6 months any serious and/or unstable medical, psychiatric, or other condition(s) that prevents the patient from providing informed consent or complying with the study organ transplantation or those on immunosuppressants chronic anticoagulation recent myocardial infarction, unstable angina, stroke, coronary artery bypass or transient ischemia attacks in the past 6 months chronic prednisone use peptic ulcer disease in past 6 months acute gastrointestinal disorders hepatitis cirrhosis GFR < 50 deep vein thrombosis in the past 6 months bone fractures in the past 6 months lithium use active malignancy substance abuse unstable psychiatric condition history of suicidal ideation enrolled in another research study related to diet and/or physical activity
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Moahad Dar, MD
Organizational Affiliation
Dept of Veteran Affairs
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Veteran Affairs, Greenville Health Care Center
City
Greenville
State/Province
North Carolina
ZIP/Postal Code
27834
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
12900694
Citation
Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE, Pratt M, Ekelund U, Yngve A, Sallis JF, Oja P. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003 Aug;35(8):1381-95. doi: 10.1249/01.MSS.0000078924.61453.FB.
Results Reference
background
PubMed Identifier
22419108
Citation
Dar MS, Chapman WH 3rd, Pender JR, Drake AJ 3rd, O'Brien K, Tanenberg RJ, Dohm GL, Pories WJ. GLP-1 response to a mixed meal: what happens 10 years after Roux-en-Y gastric bypass (RYGB)? Obes Surg. 2012 Jul;22(7):1077-83. doi: 10.1007/s11695-012-0624-1.
Results Reference
background
PubMed Identifier
15172919
Citation
Engelgau MM, Geiss LS, Saaddine JB, Boyle JP, Benjamin SM, Gregg EW, Tierney EF, Rios-Burrows N, Mokdad AH, Ford ES, Imperatore G, Narayan KM. The evolving diabetes burden in the United States. Ann Intern Med. 2004 Jun 1;140(11):945-50. doi: 10.7326/0003-4819-140-11-200406010-00035.
Results Reference
background
PubMed Identifier
23610060
Citation
Jackness C, Karmally W, Febres G, Conwell IM, Ahmed L, Bessler M, McMahon DJ, Korner J. Very low-calorie diet mimics the early beneficial effect of Roux-en-Y gastric bypass on insulin sensitivity and beta-cell Function in type 2 diabetic patients. Diabetes. 2013 Sep;62(9):3027-32. doi: 10.2337/db12-1762. Epub 2013 Apr 22.
Results Reference
background
PubMed Identifier
3360564
Citation
Kirschner MA, Schneider G, Ertel NH, Gorman J. An eight-year experience with a very-low-calorie formula diet for control of major obesity. Int J Obes. 1988;12(1):69-80.
Results Reference
background
PubMed Identifier
22449317
Citation
Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Leccesi L, Nanni G, Pomp A, Castagneto M, Ghirlanda G, Rubino F. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012 Apr 26;366(17):1577-85. doi: 10.1056/NEJMoa1200111. Epub 2012 Mar 26.
Results Reference
background

Learn more about this trial

Medically Reproducing Bariatric Surgery

We'll reach out to this number within 24 hrs